Mission Statement Overview
Cervical cancer is the most preventable of all forms of cancer, and yet it is the most common cancer affecting women in Thailand today. With adequate screening regimens and use of the right technology, early signs and risk factors can be detected and managed. VTEC’s Women Healthcare division offer the world’s leading technologies for comprehensive cervical cancer screening and diagnosis, promoting a healthier future for Thailand.
In addition to cervical cancer, the VTEC’s Women Healthcare division is committed to many aspects of healthcare for female patients. Our range of products is constantly expanding, now including Maternal fetal medicine specialized which are Down’s syndrome and genetic screening test, pregnancy monitoring and cervical dilators.
ThinPrep Pap Test
The ThinPrep Pap Test was introduced in 2003, is the most trusted, most comprehensive Pap test available today.
The ThinPrep Pap Test was one of the first Pap tests to utilise liquid-based cytology, the most significant advance in cervical cancer screening technology since the Pap test was first introduced. The ThinPrep Pap Test was launched in 1996 and quickly adopted as the most widely used Pap test in the USA- since then, invasive cervical cancers in the country have dropped by nearly 30%.
Benefits of The ThinPrep Pap Test include increased screening accuracy and superior patient comfort: multiple tests can be performed using one sample specimen, limiting the need for further samples to be collected. In addition, The ThinPrep Pap Test provides screening for human papillomavirus (HPV) making it an invaluable step in establishing all-round awareness of a patient’s state of health.
Boost the strengths of The ThinPrep Pap Test by using the ThinPrep Imaging System with Dual Review. Combining the benefits of automated hardware screening and manual review by cytotechnologists, the ThinPrep Imaging System with Dual Review increases the probability of detecting abnormalities and reduces false negative test results. www.thinprep.com
Cervista HPV HR was introduced in 2009 to provide clinicians and laboratories with a human papillomavirus (HPV) test in which they can have the utmost confidence.
Cervista HPV HR tests for all 14 oncogenic strains of HPV. The specialised internal control safeguards against false negatives due to insufficient cellularity, and there is no cross-reactivity with common low-risk HPV types that could otherwise cause false positive results.
Cervista HPV HR is the ideal next stage after an ASC-US Pap test result. The cytology results from Cervista HPV HR test indicate whether or not referral to colposcopy is necessary. With the superlative accuracy of Cervista HPV HR, clinicians, laboratories and patients can rest assured that the course of patient care will be defined strictly by their needs, not misleading results. www.hologic.com/products/clinical-diagnostics/assays-and-tests/cervista-hpv-hr-assay
Fetal Fibronectin Test
The Fetal Fibronectin (fFN) test is a powerful tool for predicting preterm birth, which was introduced in 2008
12 out of every 100 children born in Thailand are delivered preterm. Preterm birth is the most common cause of health problems in newborns today. Certain physical symptoms typically indicate that a mother is at risk of delivering prematurely. However, such symptoms can also occur when risk is low and, on the other hand, are sometimes absent leading up to a preterm birth.
The fFN test presents a more reliable method of determining the likelihood of preterm birth. Administered similarly to a Pap test, the fFN test is a safe and non-invasive method of measuring fFN levels in vaginal secretions. Usually, fFN can only be detected at the beginning of pregnancy and towards full term. Detectable levels of fFN from weeks 22 to 35 of pregnancy are a strong indicator that the patient is at high risk of delivering their baby preterm. The fFN is valuable too for its role in identifying patients who are not at risk for preterm birth. Mothers whose symptoms would otherwise be addressed with medication or bed rest can avoid disruption to their daily lives. www.ffntest.com
APTIMA HPV HR
The Aptima HPV assay was introduced in 2011, identifies high-risk HPV infections by targeting E6/E7 mRNA. Studies show that targeting E6/E7 mRNA identifies the presence and activity of a high-risk HPV infection. The Aptima HPV assay represents the next generation in cervical cancer screening - allowing clinicians to deliver maximum benefits to patients, while minimizing potential harm.
The Aptima HPV assay identifies those patients at greatest risk for developing cervical cancer, delivering the same excellent sensitivity to minimize false negative results. In fact, the Aptima HPV assay demonstrates the same excellent sensitivity as DNA-based HPV tests in numerous clinical studies involving over 50,000 women worldwide.
Unique features of the Aptima HPV assay include: The same excellent sensitivity. Increased specificity compared to DNA-based tests. FDA-approved for use with the ThinPrep Pap test. Aligned with cervical cancer screening guidelines. www.hologic.com/products/clinician-diagnostic-solutions/cervical-health/aptima-hpv-tests
APTIMA Combo2 for CT/NG assay
APTIMA Combo2 was introduced in 2014, Chlamydia and gonorrhea are the most commonly reported notifiable sexually transmitted bacterial infections. In the United States there are over 3 million new cases annually and worldwide the World Health Organization estimates the annual incidence of chlamydia to be 105.7 million and 106.1 million for gonorrhea. The Centers for Disease Control and Prevention (CDC) estimates that only 38% of sexually active young women are screened annually for chlamydia in the United States and that up to 75% of CT infected women are asymptomatic contributing to as many as 30% of CT infections progressing to PID which has been shown to cause permanent damage to a woman's reproductive system including infertility, chronic pelvic pain and ectopic pregnancy.
Studies have shown that the Aptima Combo 2 assay for chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) is clinically more sensitive to culture and non-amplified test methods and to be the most sensitive nucleic acid amplification test available. By targeting rRNA, Aptima Combo 2 enhances the sensitivity of amplification tests and virtually eliminates false negatives by removing amplificationinhibitors. www.hologic.com/products/clinician-diagnostics-solution/sexually-transmitted-infections-stis
Non-Invasive Prenatal Screening (NIPS)
VTEC’s Women Healthcare was introduced NIPS/NIPS+ in 2014 which cooperate with SOFIVA provides "Non-Invasive Prenatal Screening (NIPS) " for chromosome aneuploidy , and "Non-Invasive Prenatal Screening+ (NIPS+)" for whole chromosome aneuploidy and the 20 specific chromosomal microdeletion syndromes and cooperates with illumina® and introducing the patented technique, SAFeRTM, with its database of 1 million reports for the parents to have a safe and risk-free screening for their baby
Chromosomal abnormality is one of the main factors causing birth defects in babies. In humans, each cell normally contains 23 pairs of chromosomes, for a total of 46. Once there is any chromosomal aneuploidy or structural abnormality occurring, it leads to certain disease. Moreover, since the chromosomal abnormality happens randomly, there’s a chance of every mother having a baby with chromosomal abnormality.
SOFIVA genomics NIPS+ only needs a 10 ml blood sample from pregnant women. Cell-free fetal DNA (cffDNA) is extracted from the specimen for bioinformatics analysis of fetal chromosome at early stage by high throughput technique, Next Generation Sequencing (NGS). There’s no risk of miscarriage and infection. By combining the high throughput of NGS, bioinformatics analysis of whole genome and the global chromosome database, could perform NIPS+ to detect common chromosomal aneuploidy (Trisomy21, Trisomy18, Trisomy13, sex and other chromosome) and the 20 specific microdeletion syndromes with higher accuracy at early stage. www.sofivagenomics.com.tw/en